Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AVIR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Atea Pharmaceuticals Inc

AVIR
Current price
3.46 USD -0.02 USD (-0.57%)
Last closed 3.57 USD
ISIN US04683R1068
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 298 672 480 USD
Yield for 12 month -5.98 %
1Y
3Y
5Y
10Y
15Y
AVIR
21.11.2021 - 28.11.2021

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.50 USD

P/E Ratio

Dividend Yield

Financials AVIR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-70 090 000 USD

Current Quarter

Last Quarter

EBITDA -101 035 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -12.77 %
PEG Ratio
Return On Equity TTM -30.47 %
Wall Street Target Price 7.50 USD
Revenue TTM 192 180 000 USD
Book Value 4.80 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 295.20 %
Dividend Yield
Gross Profit TTM -80 826 000 USD
Earnings per share -1.65 USD
Diluted Eps TTM -1.65 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 264.10 %
Profit Margin

Stock Valuation AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 58.97
Price Sales TTM 1.90
Enterprise Value EBITDA -260.47
Price Book MRQ 0.73

Technical Indicators AVIR

For 52 Weeks

2.46 USD 4.15 USD
50 Day MA 3.16 USD
Shares Short Prior Month 3 319 297
200 Day MA 3.18 USD
Short Ratio 8.08
Shares Short 3 809 867
Short Percent 4.87 %